NTRK3 and non-small cell lung carcinoma: Furthermore, NTRK1 G595R and NTRK1 G667S mutations presented in a NSCLC patient, and a gatekeeper mutation (NTRK3 F617L) presented in a patient with gastrointestinal stromal tumor after disease progression with larotrectinib treatment (73).